Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction
Ploeger, B., Hoefman, S., Ruppert, M., Vis, P., Zisowsky, J., Grothey, A., Van Cutsem, E., Dochy, E., Cleton, A.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
O'Connor, J M, Ducreux, M, Petersen, L N, Öhler, L, Bergamo, F, Metges, J-P, de Groot, J W, Wang, J-Y, García Paredes, B, Dochy, E, Fiala-Buskies, S, Cervantes, A, Falcone, A
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
SO-20 Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
Vienot, A., Vernerey, D., Bouard, A., Klajer, E., Asgarov, K., Kim, S., Tournigand, C., Louvet, C., André, T., Rousseau, B., Wespiser, M., Wang, Y., Schulz, A., Dochy, E., Borg, C.
Published in Annals of oncology (01.06.2022)
Published in Annals of oncology (01.06.2022)
Get full text
Journal Article
P-327Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction
Ploeger, B, Hoefman, S, Ruppert, M, Vis, P, Zisowsky, J, Grothey, A, Van Cutsem, E, Dochy, E, Cleton, A
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Grothey, A., Hoefman, S., Ruppert, M., Vis, P., Zisowsky, J., Fiala-Buskies, S., Van Cutsem, E., Dochy, E., Cleton, A., Ploeger, B.A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
658P - Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Grothey, A., Hoefman, S., Ruppert, M., Vis, P., Zisowsky, J., Fiala-Buskies, S., Van Cutsem, E., Dochy, E., Cleton, A., Ploeger, B.A.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
658PExploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Grothey, A, Hoefman, S, Ruppert, M, Vis, P, Zisowsky, J, Fiala-Buskies, S, Van Cutsem, E, Dochy, E, Cleton, A, Ploeger, B A
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Influence of HIF-2alpha deregulation and overexpression of VEGF ligands on the response to aflibercept: Identification of predictive biomarkers
Larsen, A.K., Thouroude, S., Louadj, L., Sabbah, M., Dochy, E., de Gramont, A., Denis, J.A., Bouygues, A.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
463PReal-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
O'Connor, J M, Ducreux, M, Petersen, L N, Öhler, L, Bergamo, F, Metges, J-P, de Groot, J W, Wang, J-Y, García Paredes, B, Dochy, E, Fiala-Buskies, S, Cervantes, A, Falcone, A
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
P-221 Acquired 5-FU resistance in CRC models is accompanied by upregulation of VEGF-VEGFR1 signaling, increased migration and invasion that can be attenuated by aflibercept
Bouygues, A., Mesange, P., Ayadi, M., Chiron, M., Dochy, E., Andre, T., de Gramont, A., Larsen, A.
Published in Annals of oncology (01.06.2015)
Published in Annals of oncology (01.06.2015)
Get full text
Journal Article
Quality of Life (Qol) on the Aflibercept/Folfiri Regimen: 4Th Interim Analysis of the Global Aflibercept Safety and Health-Related Qol Program
Taieb, J., Bordonaro, R., Bencardino, K., Ciuffreda, L., Di Costanzo, F., Di Bartolomeo, M., Thomas, A.L., Kröning, H., Alfonso, P. García, Borg, C., Moore, Y., Brette, S., Zilocchi, C., Joulain, F., Naoshy, S., Garreau-Laporte, P., Dochy, E., Lledo, G., Sobrero, A.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
529PQUALITY OF LIFE (QOL) ON THE AFLIBERCEPT/FOLFIRI REGIMEN: 4TH INTERIM ANALYSIS OF THE GLOBAL AFLIBERCEPT SAFETY AND HEALTH-RELATED QOL PROGRAM
Taieb, J., Bordonaro, R., Bencardino, K., Ciuffreda, L., Di Costanzo, F., Di Bartolomeo, M., Thomas, A.L., Kröning, H., Alfonso, P. García, Borg, C., Moore, Y., Brette, S., Zilocchi, C., Joulain, F., Naoshy, S., Garreau-Laporte, P., Dochy, E., Lledo, G., Sobrero, A.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Biomarkers ER, PR, HER-2 En Topoisomerase II alpha in Correlation with Response to Neoadjuvant Chemotherapy for Primary Breast Cancer
Lambein, K., Pauwels, P., Buijsrogge, M., Denys, H., Van den Broecke, R., Depypere, H., Van Belle, S., Dochy, E., Cocquyt, V.
Published in Cancer research (Chicago, Ill.) (15.12.2009)
Published in Cancer research (Chicago, Ill.) (15.12.2009)
Get full text
Journal Article